Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Allergan Clinical trial with TFC-1067??

<< Previous

Bullboard Posts

Next >>

Comment by PeterGon Aug 01, 2023 7:04am

131 Views

Post# 35566334

RE:RE:Allergan Clinical trial with TFC-1067??

For me it is crystal clear that TFC-1067 was part of that clinical Trial. So conducted end of last year with results presented in January this year would give Allergan enough time to prepare a launch still in this year. Thoughts?

<< Previous

Bullboard Posts

Next >>

Corus reports Q1 profit drop in the face of falling revenue